Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
The addition of immunotherapy, particularly monoclonal antibodies, has revolutionized survival rates in lymphoma. These are laboratory-engineered molecules designed to recognize and bind to specific proteins on the surface of cancer cells. The most famous is Rituximab, which targets the CD20 antigen found on B cells.
When Rituximab binds to CD20, it flags the cancer cell for destruction. It recruits the patient’s own immune system (Natural Killer cells and macrophages) to attack the tagged cell (Antibody Dependent Cellular Cytotoxicity). It also activates the complement system, a cascade of proteins that punches holes in the cell membrane. Since Rituximab targets CD20 specifically, it kills B cells while sparing other healthy tissues, though it temporarily depletes normal B cells.
Newer antibodies carry payloads. Brentuximab vedotin targets CD30 (on Hodgkin cells) and is linked to a potent chemotherapy toxin. The antibody acts as a Trojan horse, binding to the cell and being internalized. Once inside, the linker breaks, releasing the toxin directly into the cancer cell, killing it while sparing surrounding healthy cells. This class of drugs is known as Antibody Drug Conjugates (ADCs).
Chimeric Antigen Receptor (CAR) T cell therapy represents the cutting edge of personalized medicine for relapsed lymphoma. It involves genetically engineering a patient’s own immune system to recognize and kill the cancer. T cells are collected from the patient’s blood via apheresis. In a laboratory, these cells are infected with a viral vector that inserts a new gene into their DNA.
This gene codes for a synthetic receptor (CAR) designed to bind a specific target on the lymphoma cell, usually CD19. The modified T cells are then expanded into the millions and infused back into the patient. Once in the bloodstream, these CAR T cells act as “living drugs.” They hunt down cells expressing CD19, bind to them, and activate a potent killing mechanism. Crucially, they can multiply within the body and persist for months or years, providing ongoing surveillance.
This therapy is reserved for patients who have failed multiple lines of chemotherapy. While highly effective, it carries unique risks, including Cytokine Release Syndrome (CRS)—a massive systemic inflammatory response causing fever and low blood pressure—and neurotoxicity. Specialized management is required during the infusion period.
While chemotherapy treats the whole body, radiation therapy provides focused, high-energy X-rays to destroy cancer cells in a specific area. Historically, large fields of radiation (such as the Mantle field) were used, but modern techniques prioritize Involved Site Radiation Therapy (ISRT). This approach targets only the lymph nodes initially involved by the lymphoma, plus a small margin, sparing healthy surrounding tissues like the heart, lungs, and breasts.
Radiation is often used in two contexts: curative and palliative. In the curative setting, it is used after chemotherapy to “clean up” any remaining sites of bulky disease, ensuring no microscopic cells survive in the most significant tumor masses. This is common in early-stage Hodgkin Lymphoma or bulky DLBCL.
In the palliative setting, low-dose radiation is excellent for shrinking large tumors that are causing pain or compression symptoms, or for treating indolent lymphomas that are localized. Modern techniques like proton therapy are being explored further to reduce the “exit dose” of radiation, minimizing long-term toxicity to vital organs located behind the tumor.
For patients whose lymphoma relapses after initial treatment or is highly aggressive, high-dose chemotherapy is required. However, the doses needed to kill the resistant lymphoma would also permanently destroy the bone marrow. Stem cell transplantation allows doctors to bypass this toxicity limit.
Autologous Stem Cell Transplant (Auto-SCT) is the most common. It is essentially a “rescue” procedure. The patient’s own healthy stem cells are collected from their blood and frozen. Then, the patient receives lethal doses of chemotherapy to wipe out the lymphoma and the bone marrow. The stored stem cells are then thawed and reinfused to “rescue” the patient, repopulating the marrow and restarting blood production.
Allogeneic Stem Cell Transplant (Allo-SCT) uses stem cells from a donor (a sibling or a matched stranger). This is riskier but offers a unique benefit: the graft-versus-lymphoma effect. The donor’s immune system recognizes the patient’s lymphoma as foreign and mounts an attack. This immunological warfare offers a potential cure for patients who have failed all other options, though it carries the risk of Graft-versus-Host Disease.
Send us all your questions or requests, and our expert team will assist you.
R-CHOP is the most common chemotherapy regimen for Non-Hodgkin Lymphoma. It consists of Rituximab (immunotherapy), Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), and Prednisone. It is usually given every 3 weeks for six cycles. The combination is designed to kill cancer cells in different ways to prevent resistance.
Most standard lymphoma regimens, such as R-CHOP and ABVD, can cause temporary hair loss (alopecia) because drugs like doxorubicin target rapidly dividing cells, including hair follicles. Hair typically begins to regrow 3 to 6 months after treatment ends. Some newer targeted therapies and immunotherapies do not cause hair loss.
“Red Devil” is a nickname patients often use for Doxorubicin (Adriamycin) because of its bright red color. It is a potent chemotherapy drug used in many lymphoma regimens. It can turn urine red for a day or two after infusion. It is highly effective but requires monitoring of heart function.
The process takes several weeks. It starts with collecting your cells (1 day), sending them to a lab for manufacturing (3 4 weeks), giving you mild chemotherapy to prepare your body (3 days), and then infusing the cells. Patients typically stay in the hospital for 1 2 weeks after infusion to monitor for side effects.
No, the actual delivery of radiation is painless, similar to getting an X-ray. You cannot feel the beam. However, side effects can develop over time, such as skin redness (like a sunburn) in the treated area, fatigue, or a sore throat if the neck is treated. These usually resolve after treatment ends.
Non-Hodgkin lymphoma (NHL) is now the most common hematologic malignancy worldwide. It has surpassed other types of hematologic cancers in incidence. The 2022 Global Cancer
Cancer is a complex disease with over 50 types. These types affect different parts of the body. Liv Hospital’s oncology experts say it’s key to
LivHospital is dedicated to providing top-notch care for lymphoma blood cancer. Lymphoma is a cancer that starts with abnormal lymphocytes, a type of white blood
Blood cancers affect the blood, bone marrow, and lymphatic system. They impact thousands of people globally. Leukemia, lymphoma, and multiple myeloma which type of blood
Hematological malignancies, including leukemia, lymphoma, and multiple myeloma, are big health worries worldwide. According to GLOBOCAN 2020, leukemia is a top reason for cancer-related deaths
Cancer and blood disorders can cause life-threatening emergencies. At Liv Hospital, we focus on world-class care for these critical cases. Our team is ready to
Leave your phone number and our medical team will call you back to discuss your healthcare needs and answer all your questions.
Your Comparison List (you must select at least 2 packages)
